Insider Selling: Glaukos (NYSE:GKOS) COO Sells 19,573 Shares of Stock

Key Points

• Glaukos COO Joseph Gilliam sold 19,573 shares on May 1 at an average price of $143.54 for about $2.81M, trimming his stake by 21.05% and reporting the transaction in an SEC filing.
• Shares fell roughly 3% to $135.98 on Monday on above‑average volume (942,743 vs. a 790,624 average), trading near its 1‑year high and with a market cap around $8 billion.
• Glaukos posted Q1 revenue of $150.57M (+41.2% YoY) and EPS of ($0.18) that beat estimates, and several analysts have raised price targets amid a consensus "Moderate Buy" target of about $138.85.

Glaukos Corporation (NYSE:GKOS - Get Free Report) COO Joseph Gilliam sold 19,573 shares of the business's stock in a transaction on Friday, May 1st. The stock was sold at an average price of $143.54, for a total value of $2,809,508.42. Following the sale, the chief operating officer owned 73,419 shares of the company's stock, valued at approximately $10,538,563.26. The trade was a 21.05% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Glaukos Trading Down 3.0%

Shares of GKOS traded down $4.24 during trading hours on Monday, hitting $135.98. 942,743 shares of the stock traded hands, compared to its average volume of 790,624. The business has a fifty day moving average of $114.02 and a 200-day moving average of $108.01. The firm has a market capitalization of $7.96 billion, a PE ratio of -41.46 and a beta of 0.94. Glaukos Corporation has a 1-year low of $73.16 and a 1-year high of $146.75. The company has a current ratio of 5.43, a quick ratio of 4.73 and a debt-to-equity ratio of 0.10.

Glaukos (NYSE:GKOS - Get Free Report) last announced its quarterly earnings data on Wednesday, April 29th. The medical instruments supplier reported ($0.18) EPS for the quarter, topping analysts' consensus estimates of ($0.30) by $0.12. Glaukos had a negative return on equity of 6.92% and a negative net margin of 34.34%.The firm had revenue of $150.57 million during the quarter, compared to analyst estimates of $137.00 million. During the same period last year, the company earned ($0.22) earnings per share. The company's revenue was up 41.2% on a year-over-year basis. Analysts expect that Glaukos Corporation will post -0.6 EPS for the current year.

Institutional Investors Weigh In On Glaukos

Several hedge funds have recently bought and sold shares of the company. UMB Bank n.a. grew its holdings in shares of Glaukos by 102.6% in the 3rd quarter. UMB Bank n.a. now owns 312 shares of the medical instruments supplier's stock valued at $25,000 after buying an additional 158 shares during the period. First Horizon Corp increased its position in shares of Glaukos by 1,715.4% in the 4th quarter. First Horizon Corp now owns 236 shares of the medical instruments supplier's stock valued at $27,000 after buying an additional 223 shares in the last quarter. Los Angeles Capital Management LLC acquired a new stake in Glaukos during the 4th quarter worth $28,000. Larson Financial Group LLC raised its stake in Glaukos by 62.0% during the 4th quarter. Larson Financial Group LLC now owns 345 shares of the medical instruments supplier's stock worth $39,000 after buying an additional 132 shares during the period. Finally, REAP Financial Group LLC bought a new position in Glaukos during the third quarter worth about $40,000. 99.04% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages recently weighed in on GKOS. Needham & Company LLC increased their price objective on shares of Glaukos from $127.00 to $136.00 and gave the company a "buy" rating in a report on Thursday. Wells Fargo & Company raised their price objective on shares of Glaukos from $135.00 to $138.00 and gave the company an "overweight" rating in a research note on Thursday. Wall Street Zen raised shares of Glaukos from a "hold" rating to a "buy" rating in a research note on Saturday. Stifel Nicolaus set a $170.00 price objective on shares of Glaukos in a research note on Thursday. Finally, Citigroup raised their price objective on shares of Glaukos from $135.00 to $140.00 and gave the company a "buy" rating in a research note on Thursday. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $138.85.

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company's core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos's flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.